Serological profiles as prognostic clues for progressive systemic scleroderma: the Italian experience

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis, vascular abnormalities, and immune system dysfunction.
• Accurate prognostic assessment in SSc is crucial for patient management and treatment strategies.
• Clinical classifications alone may not fully capture the diverse progression patterns of SSc.

Purpose of the Study:

• To investigate the correlation between distinct serological profiles and clinical manifestations in patients with progressive systemic sclerosis.
• To evaluate the prognostic value of autoantibody detection in predicting disease progression and organ involvement.
• To explore the potential of a serological classification for improving prognostic insights in SSc.

Main Methods:

• Clinical and serological evaluation of 91 patients diagnosed with progressive systemic sclerosis.
• Isolation and characterization of three main serological profiles based on autoantibody presence: anticentromere antibodies (ACA), anti-Scl-70 antibody, and anti-SSA/Ro antibodies.
• Analysis of clinical features, disease progression rates, and organ involvement associated with each serological profile.

Main Results:

• Three distinct serological profiles were identified: ACA-positive (one-third of cases) associated with later skin sclerosis, esophageal involvement, and less frequent ankyloses/ulcerations.
• Anti-Scl-70 antibody-positive patients (one-fourth of cases) exhibited the fastest progression (sclerosis <5 years), with frequent ankyloses, lung fibrosis, and joint, heart, and kidney involvement.
• Anti-SSA/Ro antibody-positive patients were uncommon but represented a severe subset with rapid progression and constant lung involvement. Other antibody profiles showed intermediate characteristics.

Conclusions:

• Serological classification, particularly identifying ACA and anti-Scl-70 antibodies, provides significant prognostic clues in systemic sclerosis.
• Distinct autoantibody profiles correlate with specific clinical phenotypes, progression rates, and organ involvement patterns.
• While further validation is needed, serological classification may offer prognostic insights that complement or surpass traditional clinical classifications in SSc management.